Key Points: Ten of 36 patients (28%) achieved an OS ≥30 months in a blinatumomab study in relapsed/refractory acute lymphoblastic leukemia. Long-term survival may be associated with T-cell expansion, B-cell depletion, and a minimal residual disease response.
Systemic sclerosis, a severe inflammatory autoimmune disease, shares a common thread with cancer through the underlying mechanism of inflammation. This inflammatory milieu not only drives the immune dysregulation characteristic of autoimmune diseases but also plays a pivotal role in the pathogenesis of cancer. Among the cellular components involved, B cells have emerged as key players in hematologic tumor and autoimmune disease, contributing to immune dysregulation and persistent tissue fibrosis in systemic sclerosis, as well as tumor progression and immune evasion in cancer. Consequently, novel therapeutic strategies targeting B cells hold promise in both conditions. Recent exploration of CD19 CAR T cells in severe systemic sclerosis patients has shown great potential, but also introduced possible risks and drawbacks associated with viral vectors, prolonged CAR T cell persistence, lengthy production timelines, high costs, and the necessity of conditioning patients with organotoxic and fertility-damaging chemotherapy. Given these challenges, alternative CD19-depleting approaches are of high interest for managing severe systemic autoimmune diseases. Here, we present the pioneering use of blinatumomab, a bispecific anti-CD3/anti-CD19 T cell engager in a patient with progressive, severe systemic sclerosis, offering a promising alternative for such challenging cases.
Acute lymphoblastic leukemia (ALL) is the most common cancer in children 1. Pediatric patients with disease refractory to last chemotherapy, relapse after allogeneic hematopoietic stem-cell transplantation (alloHSCT), or second or further relapse have a particularly poor prognosis 2. Intensive chemotherapy followed by alloHSCT after achieving remission can result in cure for some patients. However, survival is still low with this approach 3. Thus, additional treatment modalities with acceptable toxicity are needed to improve long-term survival. Blinatumomab is a bispecific T-cell engager (BiTE) antibody construct that directs CD3-positive effector memory T-cells to CD19-positive target leukemia cells. We previously reported the primary results of a phase 1-2 study of blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor ALL (BCP-ALL) 4. In that report, of the 70 patients who received the recommended phase 2 dose in either phase, 27 patients (39%; 95% confidence interval [CI], 27 to 51%) achieved complete remission (CR) within the first two cycles; of these, 52% attained negative minimal residual disease (MRD). Adverse events of interest included neurologic events (24%), cytokine release syndrome (11%), and transient, clinically non-significant elevation of alanine aminotransferase (19%), aspartate aminotransferase (14%), or bilirubin (6%). The objective of this follow-up